Fluciclovine (18F)
- Generic Name
- Fluciclovine (18F)
- Brand Names
- Axumin
- Drug Type
- Small Molecule
- Chemical Formula
- C5H8FNO2
- CAS Number
- 222727-39-1
- Unique Ingredient Identifier
- 38R1Q0L1ZE
- Background
Fluciclovine is a [18F]-tagged synthetic analog of the amino acid L-leucine. It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging. The structure of fluciclovine allows it to be uptaken by the tumoral cells by its amino acid transporter without incorporating in the metabolism within the body. Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.
- Indication
Fluciclovine is indicated as a detection agent for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. The overexpression of L-type amino acid transporters such as LAT1 and LAT3 that mediate the uptake of essential amino acids has been extensively reported as a tumoral mechanism of cell growth.
- Associated Conditions
- Prostate Cancer
- Associated Therapies
- -
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT06613841
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Emory University
- Target Recruit Count
- 22
- Registration Number
- NCT04750473
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT04134208
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
- Conditions
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Emory University
- Target Recruit Count
- 140
- Registration Number
- NCT03762759
- Locations
- 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 17
- Registration Number
- NCT03707184
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03515577
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.
- Conditions
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Bital Savir-Baruch
- Target Recruit Count
- 30
- Registration Number
- NCT03349463
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.